Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma.
asthma
pulmonary function test
spirometry
Journal
Chest
ISSN: 1931-3543
Titre abrégé: Chest
Pays: United States
ID NLM: 0231335
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
received:
17
02
2023
revised:
05
06
2023
accepted:
21
06
2023
medline:
13
11
2023
pubmed:
30
6
2023
entrez:
29
6
2023
Statut:
ppublish
Résumé
Studies examining agreement between home and clinic spirometry in patients with asthma are limited, with conflicting results. Understanding the strengths and limitations of telehealth and home spirometry is particularly important considering the SARS-CoV-2 pandemic. How well do home and clinic measurements of trough FEV This post hoc analysis used trough FEV Data from 2,436 patients (CAPTAIN trial) and 421 patients (205832 trial) were analyzed. Treatment-related improvements in FEV This post hoc comparison of home and clinic spirometry is the largest conducted in asthma. Results showed that home spirometry was less consistent than and lacked agreement with clinic spirometry, suggesting that unsupervised home readings are not interchangeable with clinic measurements. However, these findings may only be applicable to home spirometry using the specific device and coaching methods employed in these studies. Postpandemic, further research to optimize home spirometry use is needed. ClinicalTrials.gov; Nos.: NCT03012061 and NCT02924688; URL: www. gov.
Sections du résumé
BACKGROUND
Studies examining agreement between home and clinic spirometry in patients with asthma are limited, with conflicting results. Understanding the strengths and limitations of telehealth and home spirometry is particularly important considering the SARS-CoV-2 pandemic.
RESEARCH QUESTION
How well do home and clinic measurements of trough FEV
STUDY DESIGN AND METHODS
This post hoc analysis used trough FEV
RESULTS
Data from 2,436 patients (CAPTAIN trial) and 421 patients (205832 trial) were analyzed. Treatment-related improvements in FEV
INTERPRETATION
This post hoc comparison of home and clinic spirometry is the largest conducted in asthma. Results showed that home spirometry was less consistent than and lacked agreement with clinic spirometry, suggesting that unsupervised home readings are not interchangeable with clinic measurements. However, these findings may only be applicable to home spirometry using the specific device and coaching methods employed in these studies. Postpandemic, further research to optimize home spirometry use is needed.
CLINICAL TRIAL REGISTRATION
ClinicalTrials.gov; Nos.: NCT03012061 and NCT02924688; URL: www.
CLINICALTRIALS
gov.
Identifiants
pubmed: 37385337
pii: S0012-3692(23)00935-2
doi: 10.1016/j.chest.2023.06.029
pii:
doi:
Substances chimiques
Bronchodilator Agents
0
Chlorobenzenes
0
Fluticasone
CUT2W21N7U
vilanterol
028LZY775B
Banques de données
ClinicalTrials.gov
['NCT03012061', 'NCT02924688']
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1087-1096Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: Z. B., E. P., and D. S. are employees of GSK, and own stocks or shares in GSK. A. F. was an employee of GSK at the time of the studies and owns stocks or shares in GSK, and is currently an employee of AstraZeneca. G. P. is an employee of GSK and holds stocks or shares in GSK and Novartis. R. C. has received lecture fees from AstraZeneca, Chiesi, GSK, Novartis, Sanofi, and Teva; honoraria for advisory board meetings from AstraZeneca, Chiesi, GSK, Novartis, and Teva; sponsorship to attend international scientific meetings from AstraZeneca, GSK, Boehringer, Chiesi, Napp, and Sanofi; and a research grant from AstraZeneca. N. A. H. reports personal fees from Amgen, AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Mylan, Novartis, Regeneron, Sanofi Genzyme, and Teva, and for serving as an advisor or consultant. He also received research support from AstraZeneca, Boehringer Ingelheim, Genentech, Gossamer Bio, GSK, Novartis, and Sanofi Genzyme. J. O. has served on adjudication committees or data and safety monitoring boards for AstraZeneca, GSK, Novartis, and Sanofi/Regeneron, and has received grants and personal fees from GSK. H. S. has received lecture fees from AstraZeneca, GSK, Novartis, and Sanofi.